Dr. Greg Rigdon is Senior Vice President of Scientific Affairs. Greg’s drug development experience includes discovery through phase 3 clinical trials and his regulatory experience includes IND and NDA filings. Prior to Arrivo, Greg served as Director of Clinical Research at Salix Inc., where he designed clinical trials and worked with regulatory authorities for multiple gastrointestinal indications as well as hereditary angioedema.

Greg was previously Vice President, New Product Development for Icagen, Inc, a small pharmaceutical company in Research Triangle Park, NC where he built and developed teams performing drug metabolism and pharmacokinetics, in vivo pharmacology, clinical research and toxicology. Greg began his career in the pharmaceutical industry at Burroughs Wellcome (then Glaxo Wellcome) as a Wellcome Fellow, then Head of the Neuropharmacology Laboratory. He was project leader for antidepressant, central muscle relaxant and antipsychotic programs that resulted in IND filings. Greg transitioned to clinical research and became International Product Development Team Leader for a new antiepileptic drug, managing a large international group of scientists from various disciplines including clinical pharmacology, toxicology, pharmaceutics and drug metabolism.

Greg has authored/co-authored over 30 journal articles in pharmacology, neuroscience and clinical research. He is also an inventor with 4 patents and has guest lectured at the University of North Carolina at Chapel Hill and Campbell University. Greg earned his Ph.D. in Pharmacology from Texas Tech University Health Sciences Center in 1985.